Chinese M&A back on the agenda after regulatory crackdown
After a year-long barrage of regulatory intervention, Chinese corporates are re-emerging on the international deal making scene, and this time they are here to stay, writes David Rothnie.
When ChemChina announced its $44bn acquisition of Swiss pesticides group Syngenta last year, it was heralded as the arrival of Chinese conglomerates on the global M&A stage.
18 months later, and investors seem less convinced as Syngenta was forced to postpone a $7bn bond linked to the
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: email@example.com or find out more online here.